Chromogranin-A: A multifaceted cardiovascular role in health and disease

Current Medicinal Chemistry

Volumn 19, Issue 24, 2012, Pages 4042-4050

  Angelone, T ^a   Mazza, R ^a   Cerra, M C ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Acute coronary syndromes; Chromogranin A; Heart; Heart failure; Myocardial infarction

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BETA ARRESTIN; CATECHOLAMINE; CATESTATIN; CHROMOGRANIN A; CYCLIC AMP; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ESTROGEN; GUANOSINE PHOSPHATE; IMMUNOGLOBULIN G1 ANTIBODY; INSULIN; MONOCLONAL ANTIBODY; NATRIURETIC PEPTIDE RECEPTOR B; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLAMBAN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SERPININ; SEVERI; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOSTATIN 1; VS2 PROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ADRENERGIC SYSTEM; ARTICLE; BLOOD LEVEL; CALCIUM BALANCE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART CONTRACTION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LEISURE; MORTALITY; NEUROENDOCRINE DISEASE; NITROSYLATION; NONHUMAN; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REPERFUSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SURVIVAL;

ANIMALS; BIOLOGICAL MARKERS; CHROMAFFIN GRANULES; CHROMOGRANIN A; HEART DISEASES; HUMANS; HYPERTENSION; MYOCARDIUM; NATRIURETIC PEPTIDES; SERPINS;

EID: 84866705037     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802430009     Document Type: Article

References (64)

1. Banks, P.; Helle, K. The release of protein from the stimulated adrenal medulla. Biochem. J., 1965, 97,40C-41C
2. Helle, K.B.; Corti, A.;Metz-Boutigue, M.H.; Tota,B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell. Mol. Life Sci., 2007, 64,2863-2886
3. Metz-Boutigue, M.H.; Garcia-Sablone, P.; Hogue-Angeletti, R.; Aunis, D. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur. J. Biochem., 1993, 217,247-257
4. Koshimizu, H.; Cawley, N.X.; Kim,T.; Yergey, A.L.; Loh, Y.P. Serpinin: a novel chromogranin a-derived, secreted Peptide up-regulates protease nexin-1 expression and granule biogenesis in endocrine cells. Mol. Endocrinol., 2011, 25,732-744
5. Steiner, H.J.; Weiler, R.; Ludescher, C.; Schmid, K.W.; Winkler, H. J. Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J. Histochem. Cytochem., 1990, 38,845-850
6. Pieroni, M.; Corti, A.; Tota, B.; Curnis, F.; Angelone, T.; Colombo, B.; Cerra, M.C.; Bellocci, F.; Crea, F.; Maseri, A. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur. Heart J., 2007, 28,1117-1127
7. Aardal, S.; Helle, K.B. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept., 1992, 41,9-18
8. Cerra, M.C.; De Iuri, L.; Angelone, T.; Corti, A.; Tota, B. Recombinant Nterminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res. Cardiol., 2006, 101,43-52
9. Angelone, T.; Quintieri, A.M.; Brar, B.K.; Limchaiyawat, P.T.; Tota, B.; Mahata, S.K.; Cerra, MC. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology, 2008, 149,4780-4793
10. Cerra, M.C.; Gallo, M.P.; Angelone, T.; Quintieri, A.M.; Pulerà, E.; Filice, E.; Guérold, B.; Shooshtarizadeh, P.; Levi, R.; Ramella, R.; Brero, A.; Boero, O.; Metz-Boutigue, M.H.; Tota, B.; Alloatti, G. The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. FASEB J., 2008, 22,3992-4004
11. Ceconi. C.; Ferrari, R.; Bachetti, T.; Opasich, C.; Volterrani, M.; Colombo, B.; Parrinello, G.; Corti, A. Chromogranin A in heart failure. A novel neurohumoral factor and a predictor of mortality. Eur. Heart J., 2002, 23,967-974
12. Taupenot, L.; Harper, K.L.; O'Connor, D.T. The Chromogranin Secretogranin Family. N. Engl. J. Med., 2003, 348,1134-1149
13. Stridsberg, M.; Eriksson, B.; Oberg, K.; Janson, E.T. A comparison between three commercial kits for chromogranin A measurements. J. Endocrinol., 2003, 177,337-341
14. O'Connor, D.T. Chromogranin A: implications for hypertension. J. Hypertens., 1984, 2,S147-150
15. O'Connor, DT. Plasma chromogranin A. Initial studies in human hypertension. Hypertension, 1985, 7,1776-1799
16. Papewalis, C.; Kouatchoua, C.; Ehlers,M.; Jacobs, B.; Porwol, D.; Schinner, S.; Willenberg, H.S.; Anlauf, M.; Raffel, A.; Eisenhofer, G.; Neumann, H.P.; Bornstein, S.R.; Scherbaum, W.A.; Schott, M. Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma. Mol. Cell. Endocrinol., 2011, 15, 335,69-77
17. Gayen, J.R.; Gu, Y.; O'Connor, D.T.; Mahata, S.K. Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse. Endocrinology, 2009, 150,5027-5035
18. Weiergraber, M.; Pereverzev, A.; Vajna, R.; Henry, M.; Schramm, M.; Nastainczyk, W.; Grabsch, H.; Schneider, T. Immunodetection of alpha1E voltage-gated Ca(2+) channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J. Histochem. Cytochem., 2000, 48,807-819
19. Glattard, E.; Angelone, T.; Strub, J.M.; Corti, A.; Aunis, D.; Tota, B.; Metz-Boutigue, M.H.; Goumon, Y. Characterization of natural vasostatincontaining peptides in rat heart. FEBS J., 2006, 273,3311-3321
20. Biswas, N.; Curello, E.; O'Connor, D.T.; Mahata, S.K. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell. Tissue Res., 2010, 342,353-61
21. Mazza, R.; Imbrogno, S.; Tota, B. The interplay between chromogranin Aderived peptides and cardiac natriuretic peptides in cardioprotection against catecholamine-evoked stress. Regul. Pept., 2010, 165,86-94
22. Baba, H.A.; Wohlschlaeger, J. Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support. Current Cardiology Reviews,2008, 4,157-169
23. Tota, B.; Cerra, M.C.; Gattuso, A. Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a 'whipbrake' system of the endocrine heart. J. Exp. Biol., 2010, 213,3081-103
24. Tota, B.; Gentile, S.; Pasqua, T.; Bassino, E.; Koshimizu, H.; Cawley, N.X.; Cerra, M.C.; Loh, Y.P.; Angelone, T. The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac-adrenergic-like inotropes. FASEB J., 2012, Mar 29. [Epub ahead of print]
25. Tota, B.; Angelone, T.; Mazza, R.; Cerra, M.C. The chromogranin A-derived vasostatins: new players in the endocrine heart. Curr. Med. Chem., 2008,15, 1444-1451
26. Corti, A.; Mannarino, C.; Mazza, R.; Angelone, T.; Longhi, R.; Tota, B. Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatins on the isolated working frog heart. Gen. Comp. Endocrinol., 2004, 136,217-224
27. Mazza, R.; Gattuso, A.; Mannarino, C.; Brar, B.K.; Barbieri, S.F.; Tota, B.; Mahata, S.K. Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am. J. Physiol. Heart Circ. Physiol., 2008, 295,H113-H122
28. Cappello, S.; Angelone, T.; Tota, B.; Pagliaro, P.; Penna, C.; Rastaldo, R.; Corti, A.; Losano, G.; Cerra, M.C. Human recombinant chromogranin Aderived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am. J. Physiol. Heart Circ. Physiol., 2007, 293,H719-727
29. Gallo, M.P.; Levi, R.; Ramella, R.; Brero, A.; Boero, O.; Tota, B.; Alloatti, G. Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H2906-H2912
30. Ramella, R.; Boero, O.; Alloatti, G.; Angelone, T.; Levi, R.; Gallo, M.P. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycandependent mechanism. J. Cell. Biochem., 2010, 110,70-79
31. Angelone, T.; Quintieri, A.M.; Pasqua, T.; Gentile, S.; Tota, B.; Mahata, S.K., Cerra, M.C. Phosphodiesterase type-2 and NO-dependent SNitrosylation mediate the cardioinhibition of the anti-hypertensive Catestatin. Am. J. Physiol. Heart. Circ. Physiol., 2011, Nov 4. [Epub ahead of print].
32. Shaul, PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu. Rev. Physiol., 2002, 64,749-774
33. Hartell, N.A.; Archer, H.E.; Bailey, C.J. Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B. Biochem. Pharmacol., 2005, 69,781-790
34. Egger, M.; Beer, A.G.; Theurl, M.; Schgoer, W.; Hotter, B.; Tatarczyk, T.; Vasiljevic, D.; Frauscher, S.; Marksteiner, J.; Patsch, J.R.; Schratzberger, P.; Djanani, A.M.; Mahata, S.K.; Kirchmair, R. Monocyte migration: a novel effect and signaling pathways of catestatin. Eur. J. Pharmacol.,2008, 598,104-111
35. Froehlich, J.P.; Mahaney, J.E.; Keceli, G.; Pavlos, C.M.; Goldstein, R.; Redwood, A.J.; Sumbilla, C.; Lee, D.I.; Tocchetti, C.G.; Kass, D.A.; Paolocci, N.; Toscano, J.P. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry,2008, 47,13150-13152
36. Pasqua, T.; Gentile, S.; Corti, A.; Metz-Boutigue, M.H.; Cerra, M.C.; Tota, B.; Angelone, T. Chromogranin A and the heart: stimulus-induced processing and direct myocardial and coronary effects. Proceeding of 62° Meeting of The Italian Physiological Society, Acta Physiologica, 2011, 203,169
37. Vecoli, C.; Paolocci, N. When the heart sleeps. is the vagus resetting the myocardial 'redox clock'? Cardiovasc. Res., 2008, 77,609-611
38. O'Connor, D.T.; Bernstein, K.N. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N. Engl. J. Med., 1984, 311,764-770
39. Stridsberg, M.; Angeletti, R.H.; Helle, K.B. Characterization of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassay and chromatographic separation methods. J. Endocrinol, 2000, 165,703-714
40. Degorce, F.; Goumon, Y.; Jacquemart, L.; Vidaud, C.; Bellanger, L.; Pons-Anicet, D.; Seguin, P.; Metz-Boutigue, M.H,; Aunis, D. A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245). Br. J. Cancer, 1999, 79, 65-71
41. Dondossola, E.; Crippa, L.; Colombo, B.; Ferrero, E.; Corti, A. Chromogranin A regulates tumor self-seeding and dissemination. Cancer Res., 2012, 72, 449-59.
42. Rumio, C.; Dusio, G.F.; Colombo, B.; Gasparri, A.; Cardani, D.; Marcucci, F.; Corti, A. The N-Terminal Fragment of Chromogranin A, Vasostatin-1 Protects Mice From Acute or Chronic Colitis Upon Oral Administration. Dig. Dis. Sci., 2012, Jan 26. [Epub ahead of print]
43. Gustafsson, B.I.; Moss, S.F.; Pavel, M.; Tsolakis, A.V.; Kidd, M. Modlin, I.M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol., 2010, 17,2427-2443
44. Glinicki, P.; Kapuciska, R.; Jeske, W. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods. Endokrynol Pol., 2010, 61,346-50
45. Rossi, M.A.; Ramos, S.G.; Prado, C.M. Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodelling in the absence of hypertrophy. J. Hypertens., 2003, 21,993-1001
46. Vergaro, G.; Emdin, M.; Iervasi, A.; Zyw, L.; Gabutti, A.; Poletti, R.; Mammini, C.; Giannoni, A.; Fontana, M.; Passino, C. Prognostic value of plasma renin activity in heart failure. Am. J. Cardiol.,2011, 108,246-51
47. Kuhn, M.; Voss, M.; Mitko, D.; et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage sheart failure. Cardiovasc Res., 2004, 64,308-314
48. Ratti, S.; Curnis, F.; Longhi, R; Colombo, B.; Gasparri, A.; Magni, F.; Manera, E.; Metz-Boutigue, M.H.; Corti, A. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J. Biol. Chem., 2000, 275,29257-29263
49. Gasparri, A.; Sidoli, A.; Sanchez, L.P.; Longhi, R.; Siccardi, A.G.; Marchisio, P.C.; Corti, A. Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain. J. Biol. Chem., 1997, 272,20835-20843
50. Ferrero, E.; Scabini, S.; Magni, E.; et al. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J., 2004, 118,554-556
51. Dieplinger, B.; Gegenhuber, A.; Struck, J.; Poelz, W.; Langsteger, W.; Haltmayer, M.; Mueller, T. Chromogranin A and C-terminal ET-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin. Chim. Acta., 2009, 400,91-96
52. Lillie, E.O.; Mahata, M.; Khandrika, S.; Rao, F.; Bundey, R.A.; Wen, G.; Chen, Y.; Taupenot, L.; Smith, D.W.; Mahata, S.K.; Ziegler, M.G.; Cockburn, M.; Schork, N.J.; O'Connor, D.T. Heredity of endothelin secretion: human twin studies reveal the influence of polymorphism at the chromogranin A locus, a novel determinant of endothelial function. Circulation, 2007, 115,2282-2291
53. Zolk, O.; Quattek, J.; Sitzler, G.; et al. Expression of endothelin-1, endothelin converting enzyme, and endothelin receptors in chronic heart failure. Circulation, 1999, 99,2118-2123
54. Omland, T.; Dickstein, K.; Syversen, U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am. J. Med., 2003, 114,25-30
55. Estensen, M.E.; Hognestad, A.; Syversen, U.; Squire, I.; Ng, L.; Kjekshus, J.; Dickstein, K.; Omland, T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J., 2006, 152, 927-e1-6
56. Kan, H.; Finkel, M.S. Interactions between cytokines and neurohormonal systems in the failing heart. Heart Fail. Rev., 2001, 6,119-127
57. Levine, B.; Kalman, J.; Mayer, L.; et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med., 1990, 23,236-241
58. Kubota, T.; McTiernan, C.F.; Frye, C.S.; et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor alpha. Circ. Res., 1997, 81:627-635
59. Bozkurt, B.; Kribbs, S.B.; Clubb, Jr. F.J.; et al. Pathophysiologically relevant concentrations of tumor necrosis factor alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation, 1998, 97,1382-1391
60. Ferrero, E.; Magni, E.; Curnis, F.; et al. Regulation of endothelial cell shape and barrier function by chromogranin A. Ann. N. Y. Acad. Sci., 2002, 971,355-358
61. Jansson, A.M.; Røsjø, H.; Omland, T.; Karlsson, T.; Hartford, M.; Flyvbjerg, A.; Caidahl, K. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur. Heart J., 2009, 30,25-32
62. Penna, C.; Alloatti, G.; Gallo, M.P.; Cerra, M.C.; Levi, R.; Tullio, F.; Bassino, E.; Dolgetta, S.; Mahata, S.K.; Tota, B.; Pagliaro, P. Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell. Mol. Neurobiol., 2010, 30,1171-1179
63. O'Connor, D.T.; Pandlan, M.R.; Carlton, E.; Cervenka, J.H.; Hslao, R.J. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin. Chem., 1989, 35,1631-1637
64. Giusti, M.; Sidoti, M.; Augeri, C.; et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur. J. Endocrinol., 2004, 150,299-303